Tags

Type your tag names separated by a space and hit enter

Finasteride in the treatment of Japanese men with male pattern hair loss.
Eur J Dermatol. 2004 Jul-Aug; 14(4):247-54.EJ

Abstract

Finasteride is a type 2 5 alpha-reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone, a key mediator of male pattern hair loss (androgenetic alopecia). The objective of this study was to identify the optimal dosage of finasteride and to evaluate its efficacy and safety in the treatment of Japanese men with male pattern hair loss. In this double- blind randomized study, 414 Japanese men with male pattern hair loss received finasteride 1 mg (n = 139), finasteride 0.2 mg (n = 137), or placebo (n = 38) once daily for 48 weeks. Efficacy was evaluated by global photographic assessment, patient self-assessment, and investigator assessment. All efficacy endpoints showed significant improvement with finasteride therapy by 12 weeks (p < 0.05 versus placebo). At 48 weeks, 58%, 54%, and 6% of men in the finasteride 1 mg, finasteride 0.2 mg, and placebo groups, respectively, had improved based on assessments of global photographs. All efficacy endpoints were numerically superior for the 1 mg dose over the 0.2 mg dose at 48 weeks. Finasteride treatment was generally well tolerated. Finasteride 1 mg\day slows hair loss and improves hair growth in Japanese men with male pattern hair loss.

Authors+Show Affiliations

Kawashima M
Tokyo Women's Medical University, School of Medicine, Department of Dermatology 8-1, Kawada-cho, Shinjuku Tokyo, 162-8666 Japan. m-kawash@derm.twmu.ac.jp
Hayashi N
No affiliation info available
Igarashi A
No affiliation info available
Kitahara H
No affiliation info available
Maeguchi M
No affiliation info available
Mizuno A
No affiliation info available
Murata Y
No affiliation info available
Nogita T
No affiliation info available
Toda K
No affiliation info available
Tsuboi R
No affiliation info available
Ueki R
No affiliation info available
Yamada M
No affiliation info available
Yamazaki M
No affiliation info available
Matsuda T
No affiliation info available
Natsumeda Y
No affiliation info available
Takahashi K
No affiliation info available
Harada S
No affiliation info available

MeSH

5-alpha Reductase InhibitorsAdultAlopeciaDouble-Blind MethodEnzyme InhibitorsFinasterideHumansJapanMaleMiddle AgedTreatment Outcome

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15319158

Citation

Kawashima, Makoto, et al. "Finasteride in the Treatment of Japanese Men With Male Pattern Hair Loss." European Journal of Dermatology : EJD, vol. 14, no. 4, 2004, pp. 247-54.
Kawashima M, Hayashi N, Igarashi A, et al. Finasteride in the treatment of Japanese men with male pattern hair loss. Eur J Dermatol. 2004;14(4):247-54.
Kawashima, M., Hayashi, N., Igarashi, A., Kitahara, H., Maeguchi, M., Mizuno, A., Murata, Y., Nogita, T., Toda, K., Tsuboi, R., Ueki, R., Yamada, M., Yamazaki, M., Matsuda, T., Natsumeda, Y., Takahashi, K., & Harada, S. (2004). Finasteride in the treatment of Japanese men with male pattern hair loss. European Journal of Dermatology : EJD, 14(4), 247-54.
Kawashima M, et al. Finasteride in the Treatment of Japanese Men With Male Pattern Hair Loss. Eur J Dermatol. 2004 Jul-Aug;14(4):247-54. PubMed PMID: 15319158.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Finasteride in the treatment of Japanese men with male pattern hair loss. AU - Kawashima,Makoto, AU - Hayashi,Nobukazu, AU - Igarashi,Atsuyuki, AU - Kitahara,Hirohito, AU - Maeguchi,Mizue, AU - Mizuno,Atsuko, AU - Murata,Yasuko, AU - Nogita,Toshitatsu, AU - Toda,Kiyoshi, AU - Tsuboi,Ryoji, AU - Ueki,Rie, AU - Yamada,Mina, AU - Yamazaki,Masashi, AU - Matsuda,Takuma, AU - Natsumeda,Yutaka, AU - Takahashi,Kihito, AU - Harada,Shotaro, PY - 2004/8/21/pubmed PY - 2004/10/16/medline PY - 2004/8/21/entrez SP - 247 EP - 54 JF - European journal of dermatology : EJD JO - Eur J Dermatol VL - 14 IS - 4 N2 - Finasteride is a type 2 5 alpha-reductase inhibitor that inhibits conversion of testosterone to dihydrotestosterone, a key mediator of male pattern hair loss (androgenetic alopecia). The objective of this study was to identify the optimal dosage of finasteride and to evaluate its efficacy and safety in the treatment of Japanese men with male pattern hair loss. In this double- blind randomized study, 414 Japanese men with male pattern hair loss received finasteride 1 mg (n = 139), finasteride 0.2 mg (n = 137), or placebo (n = 38) once daily for 48 weeks. Efficacy was evaluated by global photographic assessment, patient self-assessment, and investigator assessment. All efficacy endpoints showed significant improvement with finasteride therapy by 12 weeks (p < 0.05 versus placebo). At 48 weeks, 58%, 54%, and 6% of men in the finasteride 1 mg, finasteride 0.2 mg, and placebo groups, respectively, had improved based on assessments of global photographs. All efficacy endpoints were numerically superior for the 1 mg dose over the 0.2 mg dose at 48 weeks. Finasteride treatment was generally well tolerated. Finasteride 1 mg\day slows hair loss and improves hair growth in Japanese men with male pattern hair loss. SN - 1167-1122 UR - https://www.unboundmedicine.com/medline/citation/15319158/Finasteride_in_the_treatment_of_Japanese_men_with_male_pattern_hair_loss_ DB - PRIME DP - Unbound Medicine ER -